Targets › SGLT2
1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.
Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P31639)
Open in Phaseline: the race on SGLT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| EMS | BERLIM 25/20 ASSOCIATION SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta | SGLT2, LDLR | Phase 3 | Dyslipidemia Associated With Type II Diabetes Mellitus | Sep 2027 |
Dyslipidemia Associated With Type II Diabetes Mellitus (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.